IL17A and colitis: Mechanistically, encenicline increases the number of FoxP3+ regulatory T cells (immunosuppressive) but reduces the number of IL-17A–producing T cells (pro-inflammatory) in DSS-treated mice, suggesting that activation of α7nAChR by encenicline alleviates colitis through altering the balance of immunosuppressive/pro-inflammatory T cells in the gut (Salaga et al., 2016).